| #1 | Gamma entrainment therapy to restore hippocampal-cortical synchrony | SST | 0.946 | $0.60 | SDA-2026-04-03-26abc |
| #2 | APOE-Dependent Autophagy Restoration | MTOR | 0.895 | $0.67 | SDA-BIOMNI-SURVIVAL- |
| #3 | Hypothesis 4: Metabolic Coupling via Lactate-Shuttling Collapse | SLC16A1, SLC16A7, LDHA, PDHA1 | 0.895 | $0.59 | SDA-2026-04-26-gap-p |
| #4 | ACSL4-Driven Ferroptotic Priming in Disease-Associated Microglia | ACSL4 | 0.891 | $0.59 | SDA-2026-04-03-gap-s |
| #5 | Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation | HCRTR1/HCRTR2 | 0.882 | $0.61 | sda-2026-04-01-gap-v |
| #6 | H6: Aberrant eIF2α Phosphorylation Creates Stalled Translation State | EIF2S1, EIF2AK3/PERK, PPP1R15B, EIF2B | 0.856 | $0.62 | SDA-2026-04-06-gap-p |
| #7 | TYROBP (DAP12) Conditional Antagonism for Early-Stage Neuroprotection | TYROBP | 0.844 | $0.65 | SDA-BIOMNI-GENE_COE- |
| #8 | Hypothesis 7: SST-SST1R/Gamma Entrainment-Enhanced Astrocyte Secretome | SST, SSTR1, SSTR2 | 0.839 | $0.58 | SDA-2026-04-26-gap-p |
| #9 | AMPK hypersensitivity in astrocytes creates enhanced mitochondrial rescue responses | PRKAA1 | 0.833 | $0.73 | sda-2026-04-01-gap-v |
| #10 | Microglial AIM2 Inflammasome as the Primary Driver of TDP-43 Proteinopathy Neuroinflammation in ALS/FTD | AIM2, CASP1, IL1B, PYCARD, TARDBP | 0.824 | $0.67 | SDA-2026-04-01-gap-2 |
| #11 | SASP-Mediated Complement Cascade Amplification | C1Q/C3 | 0.822 | $0.61 | sda-2026-04-01-gap-0 |
| #12 | STING Antagonists as ALS Therapeutics: Drug Repurposing | STING (TMEM173) | 0.821 | $0.62 | SDA-2026-04-07-gap-p |
| #13 | Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation | BDNF | 0.820 | $0.65 | SDA-2026-04-03-26abc |
| #14 | SLC7A11 System Activation Restores Cystine Uptake and GSH Synthesis to Prevent Neuronal and Endothelial Ferroptosis After Cardiac Arrest | SLC7A11 (system Xc-) and GPX4 | 0.812 | $0.64 | SDA-2026-04-26-gap-p |
| #15 | CSF1R-TREM2 Co-Agonism for Sustained Microglial Expansion | CSF1R-TREM2 | 0.808 | $0.61 | SDA-2026-04-01-gap-0 |
| #16 | Beta-Hydroxybutyrate Receptor (HCAR2) Signaling Links Ketone Deficiency to Neuroinflammation | HCAR2 | 0.808 | $0.64 | SDA-2026-04-15-gap-d |
| #17 | Neutrophil Extracellular Trap (NET) Inhibition | PADI4 | 0.806 | $0.69 | SDA-2026-04-16-gap-b |
| #18 | Targeted Butyrate Supplementation for Microglial Phenotype Modulation | GPR109A | 0.805 | $0.58 | SDA-2026-04-01-gap-2 |
| #19 | Dual-Receptor Antibody Shuttling | - | 0.803 | $0.60 | - |
| #20 | Hypothesis 1: MANF/CDNF Signaling as Primary Neuroprotective Effector | MANF, CDNF | 0.798 | $0.59 | SDA-2026-04-26-gap-p |
| #21 | Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs) | APOE | 0.795 | $0.59 | sda-2026-04-01-gap-0 |
| #22 | Senescent Microglia Resolution via Maresins-Senolytics Combination | BCL2L1 | 0.791 | $0.59 | sda-2026-04-01-gap-0 |
| #23 | Selective TLR4 Modulation to Prevent Gut-Derived Neuroinflammatory Priming | TLR4 | 0.789 | $0.68 | SDA-2026-04-01-gap-2 |
| #24 | VCP-Mediated Autophagy Enhancement | VCP | 0.787 | $0.59 | SDA-2026-04-04-gap-t |
| #25 | Competitive APOE4 Domain Stabilization Peptides | APOE | 0.784 | $0.60 | sda-2026-04-01-gap-0 |
| #26 | SASP-Driven Aquaporin-4 Dysregulation | AQP4 | 0.782 | $0.64 | sda-2026-04-01-gap-0 |
| #27 | Selective Acid Sphingomyelinase Modulation Therapy | SMPD1 | 0.782 | $0.65 | SDA-2026-04-01-gap-l |
| #28 | Selective HDAC3 Inhibition with Cognitive Enhancement | HDAC3 | 0.779 | $0.71 | SDA-2026-04-04-gap-e |
| #29 | Transcriptional Autophagy-Lysosome Coupling | FOXO1 | 0.777 | $0.63 | sda-2026-04-01-gap-0 |
| #30 | Prefrontal sensory gating circuit restoration via PV interneuron enhancement | PVALB | 0.775 | $0.65 | SDA-2026-04-03-26abc |
| #31 | Dual-Domain Antibodies with Engineered Fc-FcRn Affinity Modulation | FCGRT | 0.773 | $0.58 | sda-2026-04-01-gap-0 |
| #32 | Hypothesis 2: GPNMB-CD44 Axis as Anti-inflammatory Pathway | GPNMB, CD44 | 0.772 | $0.60 | SDA-2026-04-26-gap-p |
| #33 | TBK1-OPTN-NDP52 Phospho-Cascade Coordinates Multi-Organelle Autophagy | TBK1, OPTN (TBC1D7), NDP52/CALCOCO2 | 0.772 | $0.60 | SDA-2026-04-07-gap-p |
| #34 | Chromatin Accessibility Restoration via BRD4 Modulation | BRD4 | 0.768 | $0.60 | SDA-2026-04-04-gap-e |
| #35 | CYP46A1 Overexpression Gene Therapy | CYP46A1 | 0.768 | $0.65 | SDA-2026-04-01-gap-l |
| #36 | APOE4 Allosteric Rescue via Small Molecule Chaperones | APOE | 0.765 | $0.60 | sda-2026-04-01-gap-0 |
| #37 | SASP-Mediated Cholinergic Synapse Disruption | MMP2/MMP9 | 0.763 | $0.63 | sda-2026-04-01-gap-0 |
| #38 | Circadian Clock-Autophagy Synchronization | CLOCK | 0.763 | $0.59 | sda-2026-04-01-gap-v |
| #39 | Focused Ultrasound with Microbubble Contrast Agents for Antibody CNS Delivery | CLDN5/ZO-1 tight junction complex; KDR/VEGFR2 | 0.762 | $0.62 | SDA-2026-04-02-gap-b |
| #40 | Hypothesis 3: HepaCAM-Containing Extracellular Vesicles | HEPACAM1, HEPACAM2 | 0.762 | $0.59 | SDA-2026-04-26-gap-p |
| #41 | Cell-Type Specific TREM2 Upregulation in DAM Microglia | TREM2 | 0.761 | $0.57 | analysis-SEAAD-20260 |
| #42 | Targeted APOE4-to-APOE3 Base Editing Therapy | APOE | 0.758 | $0.64 | sda-2026-04-01-gap-0 |
| #43 | Multi-Modal Stress Response Harmonization | NR3C1/CRH/TNFA | 0.756 | $0.57 | sda-2026-04-01-gap-0 |
| #44 | Senescence-Activated NAD+ Depletion Rescue | CD38/NAMPT | 0.755 | $0.57 | sda-2026-04-01-gap-0 |
| #45 | GFAP-Positive Reactive Astrocyte Subtype Delineation | GFAP | 0.754 | $0.59 | analysis-SEAAD-20260 |
| #46 | Temporal SPP1 Inhibition During Critical Windows | SPP1 | 0.752 | $0.67 | SDA-2026-04-15-gap-p |
| #47 | VHH-Fc Fusion Constructs with Separate BBB-Targeting Moiety | FCGRT (FcRn); FCGRT-β2M complex | 0.750 | $0.59 | SDA-2026-04-02-gap-b |
| #48 | Circadian-Synchronized Proteostasis Enhancement | CLOCK/ULK1 | 0.744 | $0.57 | sda-2026-04-01-gap-0 |
| #49 | APOE Isoform Expression Across Glial Subtypes | APOE | 0.743 | $0.60 | analysis-SEAAD-20260 |
| #50 | H3: G3BP1 as Nucleation Hub for TDP-43/FUS Seeding | G3BP1, TARDBP, FUS | 0.743 | $0.59 | SDA-2026-04-06-gap-p |
| #51 | Smartphone-Detected Motor Variability Correction | DRD2/SNCA | 0.742 | $0.58 | sda-2026-04-01-gap-0 |
| #52 | Senescent Cell Mitochondrial DNA Release | CGAS/STING1/DNASE2 | 0.742 | $0.58 | sda-2026-04-01-gap-0 |
| #53 | Near-infrared light therapy stimulates COX4-dependent mitochondrial motility enhancement | COX4I1 | 0.742 | $0.59 | sda-2026-04-01-gap-v |
| #54 | APOE4-Selective Lipid Nanoemulsion Therapy | APOE | 0.742 | $0.58 | sda-2026-04-01-gap-a |
| #55 | APOE-TREM2 Interaction Modulation | TREM2 | 0.741 | $0.58 | sda-2026-04-01-gap-a |
| #56 | Epigenetic Memory Erasure via TET2 Activation | TET2 | 0.741 | $0.58 | sda-2026-04-01-gap-0 |
| #57 | PARP1 Inhibition Therapy | PARP1 | 0.738 | $0.63 | sda-2026-04-01-gap-0 |
| #58 | SIRT3-Mediated Mitochondrial Deacetylation Failure with PINK1/Parkin Mitophagy Dysfunction | SIRT3 | 0.738 | $0.57 | SDA-2026-04-03-gap-s |
| #59 | H2: Impaired Autophagy Receptor Recruitment Traps G3BP1 Granules | TBK1, SQSTM1/p62, OPTN, NDP52 | 0.737 | $0.59 | SDA-2026-04-06-gap-p |
| #60 | Aquaporin-4 Polarization Rescue | AQP4 | 0.732 | $0.60 | sda-2026-04-01-gap-0 |
| #61 | Senescence-Associated Myelin Lipid Remodeling | PLA2G6/PLA2G4A | 0.732 | $0.55 | sda-2026-04-01-gap-0 |
| #62 | Senescence-Induced Lipid Peroxidation Spreading | GPX4/SLC7A11 | 0.730 | $0.58 | sda-2026-04-01-gap-0 |
| #63 | Ubiquitin-Mediated Liquid-to-Solid Transition Prevention | G3BP1 | 0.730 | $0.61 | SDA-2026-04-07-gap-p |
| #64 | Adenosine-Astrocyte Metabolic Reset | ADORA2A | 0.730 | $0.58 | sda-2026-04-01-gap-v |
| #65 | Phase-Separated Organelle Targeting | G3BP1 | 0.729 | $0.60 | sda-2026-04-01-gap-0 |
| #66 | Synthetic Biology BBB Endothelial Cell Reprogramming | TFR1, LRP1, CAV1, ABCB1 | 0.727 | $0.57 | sda-2026-04-01-gap-0 |
| #67 | Metabolic Switch Targeting for A1→A2 Repolarization | HK2 | 0.726 | $0.57 | sda-2026-04-01-gap-0 |
| #68 | Microglial TREM2-Complement Axis Modulation | TREM2 and C3 | 0.726 | $0.60 | SDA-2026-04-03-gap-s |
| #69 | TFAM overexpression creates mitochondrial donor-recipient gradients for directed organelle trafficking | TFAM | 0.725 | $0.59 | sda-2026-04-01-gap-v |
| #70 | Astrocyte-Mediated Neuronal Epigenetic Rescue | HDAC | 0.725 | $0.57 | SDA-2026-04-04-gap-e |
| #71 | Proteostasis Enhancement via APOE Chaperone Targeting | HSPA1A | 0.724 | $0.57 | sda-2026-04-01-gap-a |
| #72 | TBK1 Loss-of-Function Amplifies C1q-Mediated Synapse Elimination Through Type I IFN Hyperactivation | TBK1 | 0.724 | $0.60 | SDA-2026-04-13-gap-p |
| #73 | Interfacial Lipid Mimetics to Disrupt Domain Interaction | APOE | 0.723 | $0.58 | sda-2026-04-01-gap-0 |
| #74 | Circadian Rhythm Entrainment of Reactive Astrocytes | BMAL1 | 0.722 | $0.57 | sda-2026-04-01-gap-0 |
| #75 | Sleep Spindle-Synaptic Plasticity Enhancement | CACNA1G | 0.721 | $0.57 | sda-2026-04-01-gap-v |
| #76 | Autophagic Receptor Sequestration via K63-Ub 'Signalone' Recognition | G3BP1 | 0.720 | $0.61 | SDA-2026-04-07-gap-p |
| #77 | ASO-Mediated Exon Skipping to Restore FUS-TAZ Chaperone Axis | FUS | 0.720 | $0.60 | SDA-2026-04-14-gap-p |
| #78 | Microglial IFN-β Priming of Motor Neuron cGAS/STING Amplification | IFNAR1/IFNAR2, STING (TMEM173), cGAS (CGAS) | 0.720 | $0.61 | SDA-2026-04-07-gap-p |
| #79 | Metabolic Reprogramming to Reverse Senescence | SIRT1,PGC1A,NAMPT | 0.720 | $0.61 | SDA-2026-04-04-gap-s |
| #80 | VCP/p97 ATPase mutations impair extraction of ubiquitinated autophagy substrates, causing proteasome-autophagy flux obstruction | VCP | 0.720 | $0.60 | SDA-2026-04-08-gap-p |
| #81 | Stress Granule Phase Separation Modulators | G3BP1 | 0.720 | $0.67 | sda-2026-04-01-gap-v |
| #82 | Magnetosonic-Triggered Transferrin Receptor Clustering | TFR1 | 0.719 | $0.57 | sda-2026-04-01-gap-0 |
| #83 | Retinal Vascular Microcirculation Rescue | PDGFRB/ANGPT1 | 0.718 | $0.57 | sda-2026-04-01-gap-0 |
| #84 | APOE Isoform Conversion Therapy | APOE | 0.718 | $0.59 | sda-2026-04-01-gap-a |
| #85 | Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides | APOE, LRP1, LDLR | 0.718 | $0.57 | sda-2026-04-01-gap-0 |
| #86 | C9orf72 DPRs Impair Autophagy Receptor Docking on Stress Granules | C9orf72, p62/SQSTM1, OPTN | 0.717 | $0.60 | SDA-2026-04-06-gap-p |
| #87 | Circadian-Synchronized LRP1 Pathway Activation | LRP1, MTNR1A, MTNR1B | 0.714 | $0.56 | sda-2026-04-01-gap-0 |
| #88 | Purinergic Signaling Polarization Control | P2RY1 and P2RX7 | 0.713 | $0.58 | sda-2026-04-01-gap-0 |
| #89 | Liquid-to-Solid Transition Pathology Reveals Granule Weak Points | TDP-43, FUS, TIA1, G3BP1 | 0.712 | $0.60 | SDA-2026-04-07-gap-p |
| #90 | Circadian Glymphatic Rescue Therapy (Melatonin-focused) | MTNR1A | 0.712 | $0.56 | sda-2026-04-01-gap-v |
| #91 | Early Proteasome Restoration Therapy | PSMC | 0.712 | $0.56 | SDA-2026-04-03-gap-a |
| #92 | Noradrenergic-Tau Propagation Blockade | ADRA2A | 0.711 | $0.59 | sda-2026-04-01-gap-v |
| #93 | HDAC3-Selective Inhibition for Clock Reset | HDAC3 | 0.710 | $0.58 | sda-2026-04-01-gap-v |
| #94 | Metabolic Circuit Breaker via Lipid Droplet Modulation | PLIN2 | 0.709 | $0.60 | sda-2026-04-01-gap-0 |
| #95 | Autophagosome Maturation Checkpoint Control | STX17 | 0.709 | $0.60 | sda-2026-04-01-gap-0 |
| #96 | Matrix Stiffness Normalization via Targeted Lysyl Oxidase Inhibition | LOX/LOXL1-4 | 0.709 | $0.59 | sda-2026-04-01-gap-v |
| #97 | Membrane Cholesterol Gradient Modulators | ABCA1/LDLR/SREBF2 | 0.708 | $0.59 | SDA-2026-04-01-gap-l |
| #98 | Orexin-Microglia Modulation Therapy | HCRTR2 | 0.707 | $0.60 | sda-2026-04-01-gap-v |
| #99 | TET2-Mediated Demethylation Rejuvenation Therapy | TET2 | 0.706 | $0.56 | sda-2026-04-01-gap-v |
| #100 | Lysosomal Enzyme Trafficking Correction | IGF2R | 0.706 | $0.60 | sda-2026-04-01-gap-0 |
| #101 | Endothelial Glycocalyx Regeneration via Syndecan-1 Upregulation | SDC1 | 0.705 | $0.58 | sda-2026-04-01-gap-v |
| #102 | Ferroptosis Inhibition for α-Synuclein Neuroprotection | GPX4 | 0.705 | $0.57 | SDA-2026-04-03-gap-a |
| #103 | Microglial Efferocytosis Enhancement via GPR32 Superagonists | CMKLR1 | 0.704 | $0.56 | sda-2026-04-01-gap-0 |
| #104 | Purinergic P2Y12 Inverse Agonist Therapy | P2RY12 | 0.703 | $0.57 | sda-2026-04-01-gap-v |
| #105 | Mitochondrial-Nuclear Epigenetic Cross-Talk Restoration | SIRT3 | 0.701 | $0.55 | SDA-2026-04-04-gap-e |
| #106 | Microglial Purinergic Reprogramming | P2RY12 | 0.701 | $0.56 | sda-2026-04-01-gap-0 |
| #107 | Nutrient-Sensing Epigenetic Circuit Reactivation | SIRT1 | 0.700 | $0.63 | SDA-2026-04-04-gap-e |
| #108 | Ataxin-2 Polyglutamine Expansions Hijack G3BP1 to Form Toxic, Irreversible Stress Granule Complexes | ATXN2 | 0.700 | $0.60 | SDA-2026-04-06-gap-p |
| #109 | Metabolic Coupling Disruption Sensitizes Motor Neuron mPTP Threshold | PDH (pyruvate dehydrogenase), MCT1/2, PDK, mPTP (ANT/VDAC/Cyclophilin D) | 0.700 | $0.59 | SDA-2026-04-07-gap-p |
| #110 | Mechanosensitive Ion Channel Reprogramming | PIEZO1 and KCNK2 | 0.700 | $0.57 | sda-2026-04-01-gap-0 |
| #111 | Granzyme B Inhibition with Serpina3n to Preserve Axonal Integrity Against Cytotoxic Attack | GZMB | 0.698 | $0.60 | SDA-2026-04-15-gap-d |
| #112 | H5: C9orf72 DPR Dipeptides Corrupt G3BP1 Condensate Properties | C9orf72, G3BP1 | 0.698 | $0.60 | SDA-2026-04-06-gap-p |
| #113 | Lysosomal Calcium Channel Modulation Therapy | MCOLN1 | 0.697 | $0.58 | sda-2026-04-01-gap-0 |
| #114 | Perforant Path Presynaptic Terminal Protection Strategy | PPARGC1A | 0.696 | $0.57 | sda-2026-04-01-gap-0 |
| #115 | Axonal RNA Transport Reconstitution | HNRNPA2B1 | 0.695 | $0.58 | sda-2026-04-01-gap-v |
| #116 | Mitochondrial Transfer Pathway Enhancement | MIRO1 | 0.695 | $0.57 | sda-2026-04-01-gap-0 |
| #117 | Complement C1q Mimetic Decoy Therapy | C1QA | 0.695 | $0.57 | sda-2026-04-01-gap-v |
| #118 | Astrocytic Lipoxin A4 Pathway Restoration via ALOX15 Gene Therapy | ALOX15 | 0.695 | $0.56 | sda-2026-04-01-gap-0 |
| #119 | Palmitoylation-Targeted BACE1 Trafficking Disruptors | BACE1 | 0.693 | $0.55 | SDA-2026-04-01-gap-l |
| #120 | Drp1-S616 Phosphorylation Fission Priming Enables t-Bid-Driven MPTP Amplification | DRP1 (DNM1L), BID | 0.693 | $0.59 | SDA-2026-04-08-gap-p |
| #121 | Ocular Immune Privilege Extension | FOXP3/TGFB1 | 0.692 | $0.56 | sda-2026-04-01-gap-0 |
| #122 | Sphingomyelin Synthase Activators for Raft Remodeling | SGMS1/SGMS2 | 0.692 | $0.56 | SDA-2026-04-01-gap-l |
| #123 | cGAS-STING Senescence Circuit Disruption | CGAS, STING1 | 0.691 | $0.58 | SDA-2026-04-03-gap-a |
| #124 | Extracellular Matrix Stiffness Modulation | PIEZO1 | 0.691 | $0.56 | sda-2026-04-01-gap-0 |
| #125 | Ganglioside Rebalancing Therapy | ST3GAL2/ST8SIA1 | 0.690 | $0.54 | SDA-2026-04-01-gap-l |
| #126 | Reelin-Mediated Cytoskeletal Stabilization Protocol | RELN | 0.689 | $0.58 | sda-2026-04-01-gap-0 |
| #127 | Cross-Seeding Prevention Strategy | TARDBP | 0.689 | $0.58 | sda-2026-04-01-gap-v |
| #128 | Hypocretin-Neurogenesis Coupling Therapy | HCRT | 0.688 | $0.57 | sda-2026-04-01-gap-v |
| #129 | Lysosomal Positioning Dynamics Modulation | LAMP1 | 0.686 | $0.56 | sda-2026-04-01-gap-0 |
| #130 | TREM2 Conformational Stabilizers for Synaptic Discrimination | TREM2 | 0.685 | $0.57 | sda-2026-04-01-gap-v |
| #131 | Pericyte Contractility Reset via Selective PDGFR-β Agonism | PDGFRB | 0.684 | $0.55 | sda-2026-04-01-gap-v |
| #132 | Focused Ultrasound with Microbubble Contrast Agents | IGFBPL1 | 0.684 | $0.60 | SDA-2026-04-06-gap-d |
| #133 | Multi-Target Synergy via Presynaptic Vesicle Hub Convergence | TH, VMAT2, DAT, GCH1, BDNF, SNCA (presynaptic hub) | 0.683 | $0.58 | SDA-2026-04-13-gap-p |
| #134 | Context-Dependent CRISPR Activation in Specific Neuronal Subtypes | Cell-type-specific essential genes | 0.682 | $0.55 | SDA-2026-04-03-gap-c |
| #135 | Differential Ubiquitin Chain Topology Creates 'Invisible' Surface on Pathological Stress Granules | TRIM21, G3BP1, OTUD1/OTUD7B | 0.682 | $0.59 | SDA-2026-04-06-gap-p |
| #136 | Temporal CAG Repeat Stabilization via CRISPR-Mediated DNA Mismatch Repair Modulation | MSH3, PMS1 | 0.681 | $0.55 | SDA-2026-04-03-gap-c |
| #137 | Flotillin-1 Stabilization Compounds | FLOT1 | 0.681 | $0.54 | SDA-2026-04-01-gap-l |
| #138 | NLRP3/Mitophagy Coupling Modulation | NLRP3 | 0.681 | $0.57 | SDA-2026-04-03-gap-i |
| #139 | R-Loop Resolution Enhancement Therapy | SETX | 0.680 | $0.56 | sda-2026-04-01-gap-v |
| #140 | Chaperone-Mediated APOE4 Refolding Enhancement | HSPA1A, HSP90AA1, DNAJB1, FKBP5 | 0.680 | $0.56 | sda-2026-04-01-gap-0 |
| #141 | Osmotic Gradient Restoration via Selective AQP1 Enhancement in Choroid Plexus | AQP1 | 0.680 | $0.55 | sda-2026-04-01-gap-v |
| #142 | Oligodendrocyte Protectin D1 Mimetic for Myelin Resolution | GPR37 | 0.680 | $0.56 | sda-2026-04-01-gap-0 |
| #143 | GPX4 Selenopeptide Mimetics as Neuroprotective Ferroptosis Blockade | GPX4 | 0.680 | $0.58 | SDA-2026-04-16-gap-f |
| #144 | ... | ... | 0.680 | $0.54 | SDA-2026-04-02-gap-a |
| #145 | Glial Neuroinflammatory Amplification by TDP-43 Pathology | TARDBP | 0.680 | $0.59 | SDA-2026-04-08-gap-p |
| #146 | Astrocytic Connexin-43 Upregulation Enhances Neuroprotective Mitochondrial Donation | GJA1 | 0.679 | $0.52 | SDA-2026-04-01-gap-2 |
| #147 | Complement C1QA Spatial Gradient in Cortical Layers | C1QA | 0.678 | $0.55 | analysis-SEAAD-20260 |
| #148 | White Matter Oligodendrocyte Protection via CXCL10 Inhibition | CXCL10 | 0.675 | $0.58 | SDA-2026-04-03-gap-a |
| #149 | Excitatory Neuron Vulnerability via SLC17A7 Downregulation | SLC17A7 | 0.675 | $0.56 | analysis-SEAAD-20260 |
| #150 | RAB27A-dependent extracellular vesicle engineering for mitochondrial cargo delivery | RAB27A | 0.674 | $0.53 | sda-2026-04-01-gap-v |
| #151 | Metabolic Reprogramming via Microglial Glycolysis Inhibition | HK2 | 0.672 | $0.56 | sda-2026-04-01-gap-v |
| #152 | Partial Neuronal Reprogramming via Modified Yamanaka Cocktail | OCT4 | 0.672 | $0.56 | SDA-2026-04-04-gap-e |
| #153 | AQP4-Dependent Astrocyte Swelling Exacerbates Excitotoxic Neuronal Death via Dysfunction of the Glutamate-Gln Cycle | AQP4; SLC1A2 (GLT-1) | 0.670 | $0.58 | SDA-2026-04-07-gap-p |
| #154 | OPTN/TBK1 mutations create selective vulnerability by blocking PINK1-Parkin-independent mitophagy in lower motor neurons | OPTN | 0.670 | $0.59 | SDA-2026-04-08-gap-p |
| #155 | Enhancing Vagal Cholinergic Signaling to Restore Gut-Brain Anti-Inflammatory Communication | CHRNA7 | 0.669 | $0.55 | SDA-2026-04-01-gap-2 |
| #156 | Astrocyte MCT1/MCT4 Ratio Disruption with Metabolic Uncoupling | SLC16A1 | 0.668 | $0.55 | SDA-2026-04-03-gap-s |
| #157 | Aquaporin-4 Polarization Enhancement via TREK-1 Channel Modulation | KCNK2 | 0.668 | $0.55 | sda-2026-04-01-gap-v |
| #158 | Mitochondrial-Lysosomal Contact Site Engineering | RAB7A | 0.668 | $0.55 | sda-2026-04-01-gap-0 |
| #159 | Lipid Droplet Dynamics as Phenotype Switches | DGAT1 and SOAT1 | 0.666 | $0.56 | sda-2026-04-01-gap-0 |
| #160 | GAP43-mediated tunneling nanotube stabilization enhances neuroprotective mitochondrial transfer | GAP43 | 0.666 | $0.57 | sda-2026-04-01-gap-v |
| #161 | Complement C1q Subtype Switching | C1QA | 0.665 | $0.57 | sda-2026-04-01-gap-0 |
| #162 | Stathmin-2 Splice Switching to Prevent Axonal Degeneration Across the ALS-FTD-AD Spectrum | STMN2 (stathmin-2), PTBP1/PTBP2 | 0.664 | $0.60 | SDA-2026-04-13-gap-2 |
| #163 | RNA Granule Nucleation Site Modulation | G3BP1 | 0.662 | $0.58 | sda-2026-04-01-gap-0 |
| #164 | Chronic cGAS/STING Hyperactivation Drives Progressive Neurodegeneration Through Sustained Type I Interferon Signaling | cGAS (CGAS) / STING (TMEM173) / IFNAR1/2 | 0.661 | $0.58 | SDA-2026-04-07-gap-p |
| #165 | PARP1 Inhibition Blocks Poly(PR)-Triggered DNA Damage and Subsequent p53 Activation | PARP1 | 0.661 | $0.57 | SDA-2026-04-15-gap-p |
| #166 | Biorhythmic Interference via Controlled Sleep Oscillations | GABRA1 | 0.661 | $0.56 | sda-2026-04-01-gap-0 |
| #167 | SASP Modulation Rather Than Cell Elimination | NFKB1,IL1B,BDNF | 0.660 | $0.60 | SDA-2026-04-04-gap-s |
| #168 | Axonal Transport Defect: C9orf72 hexanucleotide expansion impairs retrograde autophagosome transport in motor neuron axons | C9orf72 | 0.660 | $0.58 | SDA-2026-04-08-gap-p |
| #169 | Temporal TET2-Mediated Hydroxymethylation Cycling | TET2 | 0.657 | $0.55 | SDA-2026-04-04-gap-e |
| #170 | Mitochondrial RNA Granule Rescue Pathway | SYNCRIP | 0.656 | $0.55 | sda-2026-04-01-gap-v |
| #171 | Cyclophilin D (CypD) Displacement by Mitochondrial TDP-43 | PPID (Cyclophilin D) | 0.656 | $0.58 | SDA-2026-04-08-gap-p |
| #172 | Optogenetic Microglial Deactivation via Engineered Inhibitory Opsins | CX3CR1 | 0.655 | $0.56 | sda-2026-04-01-gap-v |
| #173 | Arginine Methylation Enhancement Therapy | PRMT1 | 0.653 | $0.60 | sda-2026-04-01-gap-0 |
| #174 | Microbial Inflammasome Priming Prevention | NLRP3, CASP1, IL1B, PYCARD | 0.653 | $0.66 | SDA-2026-04-01-gap-2 |
| #175 | KDM6A-Mediated H3K27me3 Rejuvenation | KDM6A | 0.653 | $0.57 | sda-2026-04-01-gap-v |
| #176 | Nucleolar Stress Response Normalization | NPM1 | 0.653 | $0.56 | sda-2026-04-01-gap-v |
| #177 | The Mitochondrial-Lysosomal Metabolic Coupling Dysfunction | TFEB | 0.652 | $0.54 | SDA-2026-04-02-gap-v |
| #178 | Oligodendrocyte White Matter Vulnerability | MOG | 0.651 | $0.55 | SDA-2026-04-03-gap-a |
| #179 | Mitochondrial Calcium Buffering Enhancement via MCU Modulation | MCU | 0.650 | $0.55 | sda-2026-04-01-gap-0 |
| #180 | NRF2-KEAP1 Pathway Activation to Coordinate Multi-Layer Antioxidant Defense | NRF2 (NFE2L2), KEAP1 | 0.650 | $0.56 | SDA-2026-04-16-gap-f |
| #181 | APOE-Mediated Synaptic Lipid Raft Stabilization | SPTLC1 | 0.649 | $0.54 | sda-2026-04-01-gap-a |
| #182 | Glial Glycocalyx Remodeling Therapy | HSPG2 | 0.649 | $0.55 | sda-2026-04-01-gap-0 |
| #183 | Apoptosis-Senescence Decision Point Intervention | TP53,BAX,BAK1,CASP3 | 0.649 | $0.57 | SDA-2026-04-04-gap-s |
| #184 | IL-10-Producing B10 Cells Establish AQP4-Specific Peripheral Tolerance Through Macrophage Reprogramming | IL10, CSF1R, CD40 | 0.648 | $0.55 | SDA-2026-04-13-gap-p |
| #185 | ALS-Linked OPTN/TBK1 Mutations Impair Phosphorylation Cascade Required for Pathological SG Recognition | OPTN, TBK1 | 0.648 | $0.57 | SDA-2026-04-06-gap-p |
| #186 | DNMT1-Targeting Antisense Oligonucleotide Reset | DNMT1 | 0.648 | $0.55 | sda-2026-04-01-gap-v |
| #187 | HCN1-Mediated Resonance Frequency Stabilization Therapy | HCN1 | 0.648 | $0.54 | sda-2026-04-01-gap-0 |
| #188 | Mitochondrial SPM Synthesis Platform Engineering | ALOX5 | 0.647 | $0.53 | sda-2026-04-01-gap-0 |
| #189 | Epigenetic Reprogramming of Microglial Memory | DNMT3A, HDAC1/2 | 0.647 | $0.57 | SDA-2026-04-04-gap-2 |
| #190 | Grid Cell-Specific Metabolic Reprogramming via IDH2 Enhancement | IDH2 | 0.646 | $0.55 | sda-2026-04-01-gap-0 |
| #191 | Synthetic Biology Rewiring via Orthogonal Receptors | CNO | 0.645 | $0.56 | sda-2026-04-01-gap-0 |
| #192 | Ephrin-B2/EphB4 Axis Manipulation | EPHB4 | 0.645 | $0.55 | sda-2026-04-01-gap-0 |
| #193 | MCU Calcium Overload via MFN2/GRP75/VDAC1 MAM Dysfunction | MFN2, GRP75 (HSPA9), MCU (MICU1/2) | 0.644 | $0.57 | SDA-2026-04-08-gap-p |
| #194 | Dual Calpain/Cathepsin B Inhibition as Primary Neuroprotective Strategy | - | 0.644 | $0.56 | SDA-2026-04-15-gap-p |
| #195 | HDAC6 Selective Inhibition to Restore Acetylation Balance and Microtubule Stability | HDAC6 | 0.643 | $0.55 | SDA-2026-04-13-gap-d |
| #196 | Targeting Bacterial Curli Fibrils to Prevent α-Synuclein Cross-Seeding | CSGA | 0.642 | $0.54 | SDA-2026-04-01-gap-2 |
| #197 | Glycine-Rich Domain Competitive Inhibition | TARDBP | 0.640 | $0.56 | sda-2026-04-01-gap-0 |
| #198 | Small Molecule Modulation of Phase Separation | FUS, TDP-43, G3BP1 | 0.640 | $0.57 | SDA-2026-04-07-gap-p |
| #199 | Heterogeneous astrocyte activation states differentially impact neuronal survival across AD progression | GFAP | 0.640 | $0.55 | SDA-2026-04-04-analy |
| #200 | Transglutaminase-2 Cross-Linking Inhibition Strategy | TGM2 | 0.639 | $0.56 | SDA-2026-04-01-gap-9 |
| #201 | Acid-Degradable LNP-Mediated Prenatal CRISPR Intervention for Severe Neurodevelopmental Forms | SOD1, HTT, TARDBP | 0.638 | $0.56 | SDA-2026-04-03-gap-c |
| #202 | TREM2-Dependent Microglial Phagocytosis Acts as a Strain Selection Filter | TREM2 | 0.636 | $0.58 | SDA-2026-04-15-gap-d |
| #203 | HSP90-Tau Disaggregation Complex Enhancement | HSP90AA1 | 0.634 | $0.61 | SDA-2026-04-04-gap-t |
| #204 | G3BP1 NTF2L Domain-Mediated mRNP Scaffold Creates Core Exclusion Zone for Autophagy Receptors | G3BP1 | 0.633 | $0.57 | SDA-2026-04-08-gap-p |
| #205 | Palmitoylethanolamide-Based Endocannabinoid Therapy | PPARA | 0.633 | $0.54 | SDA-2026-04-16-gap-b |
| #206 | TREM2 R47H Variant Correction — AAV-Mediated Rescue of Common Risk Allele | TREM2 | 0.631 | $0.57 | SDA-2026-04-02-gap-0 |
| #207 | Disease-Associated Microglia Metabolic Reprogramming | TREM2 | 0.631 | $0.57 | SDA-2026-04-03-gap-s |
| #208 | FOXO3-Longevity Pathway Epigenetic Reprogramming | FOXO3 | 0.630 | $0.55 | sda-2026-04-01-gap-v |
| #209 | Programmable Neuronal Circuit Repair via Epigenetic CRISPR | NURR1, PITX3, neuronal identity transcription factors | 0.630 | $0.52 | SDA-2026-04-03-gap-c |
| #210 | Multi-Modal CRISPR Platform for Simultaneous Editing and Monitoring | Disease-causing mutations with integrated reporters | 0.629 | $0.52 | SDA-2026-04-03-gap-c |
| #211 | Quantum Coherence Disruption in Cellular Communication | TUBB3 | 0.627 | $0.54 | sda-2026-04-01-gap-0 |
| #212 | Cardiovascular-Neuroinflammatory Dual Targeting | TNF/IL6 | 0.627 | $0.55 | SDA-2026-04-04-gap-2 |
| #213 | Peripheral-to-Central Inflammation Circuit Breaker | IL1B | 0.626 | $0.57 | SDA-2026-04-16-gap-b |
| #214 | H7: Aberrant RNA Template Switching Converts Granules to Aggregation Prone | G3BP1, DDX3X, DDX6 | 0.625 | $0.57 | SDA-2026-04-06-gap-p |
| #215 | Heat Shock Protein 70 Disaggregase Amplification | HSPA1A | 0.625 | $0.56 | sda-2026-04-01-gap-0 |
| #216 | Synaptic Phosphatidylserine Masking via Annexin A1 Mimetics | ANXA1 | 0.625 | $0.54 | sda-2026-04-01-gap-v |
| #217 | Autophagy-Senescence Axis Therapeutic Window | ATG7,BCL2,BCL2L1 | 0.624 | $0.58 | SDA-2026-04-04-gap-s |
| #218 | Serine/Arginine-Rich Protein Kinase Modulation | SRPK1 | 0.624 | $0.53 | sda-2026-04-01-gap-0 |
| #219 | TFEB-PGC1α Mitochondrial-Lysosomal Decoupling | TFEB | 0.622 | $0.53 | SDA-2026-04-03-gap-a |
| #220 | Cholesterol-CRISPR Convergence Therapy for Neurodegeneration | HMGCR, LDLR, APOE regulatory regions | 0.622 | $0.54 | SDA-2026-04-03-gap-c |
| #221 | TOM/TIM Complex Disruption Triggering Mitochondrial Integrated Stress Response (mtISR) | TOMM40, TOMM70, CLPP | 0.622 | $0.57 | SDA-2026-04-08-gap-p |
| #222 | Pharmacological Enhancement of APOE4 Glycosylation | ST6GAL1, FUT8 | 0.622 | $0.52 | sda-2026-04-01-gap-0 |
| #223 | Vagal Afferent Microbial Signal Modulation | GLP1R, BDNF | 0.621 | $0.55 | SDA-2026-04-01-gap-2 |
| #224 | Designer TRAK1-KIF5 fusion proteins accelerate therapeutic mitochondrial delivery | TRAK1_KIF5A | 0.621 | $0.54 | sda-2026-04-01-gap-v |
| #225 | Sphingolipid Metabolism Reprogramming | CERS2 | 0.620 | $0.54 | sda-2026-04-01-gap-0 |
| #226 | Cross-Cell Type Synaptic Rescue via Tripartite Synapse Restoration | SYN1, SLC1A2, and CX3CR1 | 0.620 | $0.56 | SDA-2026-04-03-gap-s |
| #227 | Synaptic RNA Metabolism Dysregulation | TARDBP | 0.620 | $0.56 | SDA-2026-04-08-gap-p |
| #228 | Microglial xCT/SLC7A11 Selective Inhibition to Reduce Non-Cell-Autonomous Glutamate Toxicity | SLC7A11 | 0.620 | $0.55 | SDA-2026-04-16-gap-f |
| #229 | Nuclear TDP-43 Depletion Drives Synaptic Splicing Dysregulation in ALS-FTD | TARDBP, splicing targets (Sortilin1, Synaptojanin1) | 0.620 | $0.56 | SDA-2026-04-02-gap-2 |
| #230 | Enhanced MCU Activity Primes mPTP Opening in Motor Neurons | MCU complex (MICU1/MICU2), mitochondrial calcium regulatory proteins | 0.620 | $0.56 | SDA-2026-04-07-gap-p |
| #231 | TREM2-Dependent Microglial Senescence Transition | TREM2 | 0.618 | $0.55 | SDA-BIOMNI-SCRNA_AN- |
| #232 | TREM2-mediated microglial tau clearance enhancement | TREM2 | 0.618 | $0.67 | SDA-2026-04-04-gap-t |
| #233 | Low Complexity Domain Cross-Linking Inhibition | TGM2 | 0.617 | $0.54 | sda-2026-04-01-gap-0 |
| #234 | MFN2-PACS2 Axis at MAMs Coordinates Mitophagy-ER-Phagy Sync | MFN2 (MFN2), PACS2 (PACS2) | 0.615 | $0.56 | SDA-2026-04-07-gap-p |
| #235 | Blocking AGE-RAGE Signaling in Enteric Glia to Prevent Neuroinflammatory Cascade | AGER | 0.613 | $0.52 | SDA-2026-04-01-gap-2 |
| #236 | FUS Mutations Alter Stress Granule Material Properties to Confer Autophagy Resistance | FUS | 0.613 | $0.54 | SDA-2026-04-06-gap-p |
| #237 | Trinucleotide Repeat Sequestration via CRISPR-Guided RNA Targeting | HTT, DMPK, repeat-containing transcripts | 0.613 | $0.55 | SDA-2026-04-03-gap-c |
| #238 | Restoring Neuroprotective Tryptophan Metabolism via Targeted Probiotic Engineering | TDC | 0.612 | $0.53 | SDA-2026-04-01-gap-2 |
| #239 | SIRT6-NAD+ Axis Enhancement Therapy | SIRT6 | 0.612 | $0.54 | sda-2026-04-01-gap-v |
| #240 | Complement-Mediated Synaptic Pruning Dysregulation | C1QA | 0.612 | $0.53 | SDA-2026-04-03-gap-a |
| #241 | Synaptic Pruning Precision Therapy | C1QA, C3, CX3CR1, CX3CL1 | 0.612 | $0.57 | SDA-2026-04-04-gap-2 |
| #242 | Epigenetic Memory Reprogramming for Alzheimer's Disease | BDNF, CREB1, synaptic plasticity genes | 0.611 | $0.55 | SDA-2026-04-03-gap-c |
| #243 | GDNF Gradient Establishment by Schwann Cells Enables Motor Re-innervation | GDNF | 0.610 | $0.59 | SDA-2026-04-14-gap-p |
| #244 | Tau Cross-Seeding and Interaction | MAPT | 0.610 | $0.56 | SDA-2026-04-08-gap-p |
| #245 | ALS-Associated G3BP1 Mutations Shift Phase Separation Equilibrium Toward Aberrant Condensate Stabilization | G3BP1 | 0.610 | $0.56 | SDA-2026-04-06-gap-p |
| #246 | The Glial Ketone Metabolic Shunt Hypothesis | HMGCS2 | 0.608 | $0.55 | SDA-2026-04-02-gap-v |
| #247 | Correcting Gut Microbial Dopamine Imbalance to Support Systemic Dopaminergic Function | DDC | 0.606 | $0.52 | SDA-2026-04-01-gap-2 |
| #248 | TREM2-Microglial Clearance Enhancement as Common Mechanism for Injury Prevention | TREM2 | 0.604 | $0.58 | SDA-2026-04-14-gap-p |
| #249 | LRP1-Dependent Tau Uptake Disruption | LRP1 | 0.600 | $0.72 | SDA-2026-04-04-gap-t |
| #250 | Cytosolic TDP-43 aggregation sequesters SNAP29 and syntaxin-17, blocking autophagosome-lysosome fusion | TARDBP | 0.600 | $0.56 | SDA-2026-04-08-gap-p |
| #251 | Metabolic Reprogramming via Coordinated Multi-Gene CRISPR Circuits | PGC1A, SIRT1, FOXO3, mitochondrial biogenesis genes | 0.599 | $0.52 | SDA-2026-04-03-gap-c |
| #252 | Glycosaminoglycan Template Disruption Approach | HSPG2 | 0.597 | $0.53 | SDA-2026-04-01-gap-9 |
| #253 | Brain Insulin Resistance with Glucose Transporter Dysfunction | GLUT3/GLUT4 | 0.596 | $0.55 | SDA-2026-04-02-gap-v |
| #254 | Aβ-induced downregulation of circPDS5B derepresses TDP-43 mRNA translation in limbic neurons, causing proteostatic overload and aggregation specifically in AD | circPDS5B (hsa_circ_0083342) / TARDBP | 0.595 | $0.55 | SDA-2026-04-07-gap-p |
| #255 | Aβ42 oligomers drive TDP-43 phosphorylation at s409/410 through CDK5/p25 activation specifically in AD, generating a phospho-signature distinct from ALS/FTLD | CDK5R1 (p25 regulatory subunit) | 0.595 | $0.55 | SDA-2026-04-07-gap-p |
| #256 | Netrin-1 Gradient Restoration | NTN1 | 0.595 | $0.54 | sda-2026-04-01-gap-0 |
| #257 | VCP-Mediated Autophagy Enhancement | VCP | 0.595 | $0.64 | SDA-2026-04-04-gap-t |
| #258 | TREM2-C1Q Competitive Binding to Prevent Complement-Mediated Cholinergic Synapse Loss | TREM2,C1Q | 0.591 | $0.56 | SDA-2026-04-16-gap-p |
| #259 | CHIP-mediated ubiquitination selectively targets oligomeric pathologic conformers for proteasomal degradation | STUB1 (CHIP), HSPA8, VCP, PSMD4 | 0.590 | $0.55 | SDA-2026-04-10-gap-d |
| #260 | Multiplexed Base Editing for Simultaneous Neuroprotective Gene Activation | SOD1, TARDBP, BDNF, GDNF, IGF-1 | 0.590 | $0.54 | SDA-2026-04-03-gap-c |
| #261 | Cardiovascular-Neuroinflammation Crosstalk Interruption | IL1B, TNFA, NLRP3 | 0.587 | $0.56 | SDA-2026-04-04-gap-2 |
| #262 | ALS-Associated G3BP1/2 Mutations Disrupt TRIM21 Binding Interfaces | G3BP1, G3BP2 | 0.585 | $0.55 | SDA-2026-04-06-gap-p |
| #263 | NOMO1-Mediated Neuronal Resilience Enhancement | NOMO1 | 0.584 | $0.55 | SDA-2026-04-03-gap-a |
| #264 | PIKFYVE Inhibition Activates Aggregate Exocytosis via PI(3,5)P2→TRPML1→Calcineurin→TFEB Cascade in ALS Motor Neurons | PIKFYVE/MCOLN1/PPP3CB/TFEB | 0.584 | $0.54 | SDA-2026-04-13-gap-p |
| #265 | TREM2-Mediated Selective Aggregate Clearance Pathway | TREM2 | 0.584 | $0.52 | SDA-2026-04-01-gap-9 |
| #266 | IGFBPL1-Mediated Homeostatic Restoration | IGFBPL1 | 0.584 | $0.56 | SDA-2026-04-04-gap-2 |
| #267 | Extracellular Vesicle Biogenesis Modulation | CHMP4B | 0.582 | $0.58 | SDA-2026-04-04-gap-t |
| #268 | ALOX15 Inhibition Combined with Selenium Augmentation for Synergistic Ferroptosis Blockade | ALOX15, SELENOP | 0.580 | $0.54 | SDA-2026-04-16-gap-f |
| #269 | AQP4 Missorting in Reactive Astrocytes Drives Glymphatic Failure in Chronic Neurodegeneration | AQP4; STAT3; MMP9 | 0.580 | $0.55 | SDA-2026-04-07-gap-p |
| #270 | Neuroinflammation-Driven TDP-43 Mislocalization via Microglial APOE4 Signaling | NLRP3, LRP1, IL1B, TNF | 0.580 | $0.54 | SDA-2026-04-07-gap-p |
| #271 | Nuclear Export Deficits Increase Cytosolic TDP-43 Burden | XPO1/CRM1, ALYREF, THOC1/THOC2, TDP-43 NLS | 0.580 | $0.55 | SDA-2026-04-07-gap-p |
| #272 | Synaptic Vesicle Tau Capture Inhibition | SNAP25 | 0.578 | $0.59 | SDA-2026-04-04-gap-t |
| #273 | TBK1 Phosphorylation State Creates Phospho-Regulated Peripheral Retention Threshold | TBK1 | 0.577 | $0.55 | SDA-2026-04-08-gap-p |
| #274 | HSP90-Tau Disaggregation Complex Enhancement | HSP90AA1 | 0.575 | $0.74 | SDA-2026-04-04-gap-t |
| #275 | PINK1/PARK2-Mediated Mitophagy Enhancement for Neuroinflammation Control | PINK1 | 0.571 | $0.55 | SDA-2026-04-03-gap-i |
| #276 | Tau-Independent Microtubule Stabilization via MAP6 Enhancement | MAP6 | 0.567 | $0.56 | sda-2026-04-01-gap-0 |
| #277 | Vascular-Glial Interface Restoration | CLDN5 | 0.566 | $0.54 | SDA-2026-04-03-gap-s |
| #278 | CX43 hemichannel engineering enables size-selective mitochondrial transfer | GJA1 | 0.566 | $0.55 | sda-2026-04-01-gap-v |
| #279 | Astroglial Gap Junction Coordination via Connexin-43 Phosphorylation Modulation | GJA1 | 0.566 | $0.58 | sda-2026-04-01-gap-v |
| #280 | Fractalkine Axis Amplification via CX3CR1 Positive Allosteric Modulators | CX3CR1 | 0.563 | $0.53 | sda-2026-04-01-gap-v |
| #281 | C9orf72-SMCR8-WDR41 Complex Dysfunction in C9-ALS Rescued by PIKFYVE Inhibition via Lysosomal Exocytosis Restoration | C9orf72/SMCR8/RAB7A/PIKFYVE | 0.562 | $0.56 | SDA-2026-04-13-gap-p |
| #282 | TRPML1-PINK1/Parkin Axis Coordinates Mitophagy with Lysosomal Biogenesis | MCOLN1, PINK1, PARK2, TFEB, LRRK2 | 0.560 | $0.55 | SDA-2026-04-16-gap-d |
| #283 | Temporal cGAS-STING Activation Stage-Specific Therapeutic Targeting | STING (TMEM173) | 0.560 | $0.54 | SDA-2026-04-07-gap-p |
| #284 | GCH1/BH4 Axis Stabilization for Dual Ferroptosis and Mitochondrial Protection | GCH1, BH4 | 0.560 | $0.54 | SDA-2026-04-16-gap-f |
| #285 | Circadian-Gated Maresin Biosynthesis Amplification | ALOX12 | 0.557 | $0.56 | sda-2026-04-01-gap-0 |
| #286 | Gut-Brain Axis Microbiome Modulation | GPR43, GPR109A | 0.557 | $0.54 | SDA-2026-04-04-gap-2 |
| #287 | Profilin-1 Cytoskeletal Checkpoint Enhancement | PFN1 | 0.554 | $0.53 | SDA-2026-04-03-gap-a |
| #288 | Dual NF-κB/MMP Inhibition Strategy | NFKB1 | 0.554 | $0.55 | SDA-2026-04-16-gap-b |
| #289 | P2RX7-Mediated Exosome Secretion Blockade | P2RX7 | 0.552 | $0.57 | SDA-2026-04-04-gap-t |
| #290 | Liquid-Liquid Phase Separation Modifier Therapy | G3BP1 | 0.551 | $0.53 | SDA-2026-04-01-gap-9 |
| #291 | H63D HFE Genotype-Guided Iron Chelation Therapy for Subset-Selected ALS Patients | HFE (H63D variant) | 0.550 | $0.53 | SDA-2026-04-16-gap-f |
| #292 | Digital Twin-Guided Metabolic Reprogramming | PPARGC1A/PRKAA1 | 0.550 | $0.54 | sda-2026-04-01-gap-0 |
| #293 | Oligodendrocyte DNA Repair Enhancement | PARP1 | 0.550 | $0.52 | SDA-2026-04-03-gap-s |
| #294 | H7: NEAT1 Epigenetic Rewiring Under Proteotoxic Stress | NEAT1, METTL14, YTHDC1 (m6A reader) | 0.550 | $0.53 | SDA-2026-04-04-gap-2 |
| #295 | Miro1-Mediated Mitochondrial Trafficking Enhancement Therapy | RHOT1 | 0.549 | $0.51 | SDA-2026-04-01-gap-2 |
| #296 | Trans-Synaptic Adhesion Molecule Modulation | NLGN1 | 0.544 | $0.53 | SDA-2026-04-04-gap-t |
| #297 | HSP70 Co-chaperone DNAJB6 Universal Cross-Seeding Inhibitor | DNAJB6 | 0.544 | $0.51 | SDA-2026-04-01-gap-9 |
| #298 | Temporal Decoupling via Circadian Clock Reset | CLOCK | 0.543 | $0.58 | sda-2026-04-01-gap-0 |
| #299 | N-acetylation Deficiency as Novel Metabolic Vulnerabilities in Sporadic ALS | NAA10, NAA20, NAA80 | 0.540 | $0.54 | SDA-2026-04-02-gap-2 |
| #300 | Lysosomal Membrane Repair Enhancement | CHMP2B | 0.538 | $0.56 | sda-2026-04-01-gap-0 |
| #301 | Ferroptosis as Disease-Modifying Amplifier | - | 0.538 | $0.53 | SDA-2026-04-18-gap-d |
| #302 | Glymphatic System-Enhanced Antibody Clearance Reversal | AQP4 | 0.537 | $0.58 | sda-2026-04-01-gap-0 |
| #303 | Blood-Brain Barrier SPM Shuttle System | TFRC | 0.533 | $0.57 | sda-2026-04-01-gap-0 |
| #304 | Gut Barrier Permeability-α-Synuclein Axis Modulation | CLDN1, OCLN, ZO1, MLCK | 0.533 | $0.53 | SDA-2026-04-01-gap-2 |
| #305 | Lactate/Pyruvate Ratio Dynamics in CSF as a Neuroinflammation-Metabolism Interface Biomarker | LDHA, TREM2 | 0.532 | $0.56 | SDA-2026-04-04-SDA-2 |
| #306 | EV-Mediated Epigenetic Reprogramming | EVs/miRNAs | 0.532 | $0.53 | sda-2026-04-12-ev-ad |
| #307 | Cryptic Exon Silencing Restoration | TARDBP | 0.531 | $0.55 | sda-2026-04-01-gap-v |
| #308 | Astrocytic Lactate Shuttle Enhancement for Grid Cell Bioenergetics | SLC16A2 | 0.529 | $0.55 | sda-2026-04-01-gap-0 |
| #309 | PINK1/Parkin-Independent Mitophagy Bypass for Enhanced Donor Mitochondria | BNIP3/BNIP3L | 0.529 | $0.51 | SDA-2026-04-01-gap-2 |
| #310 | TREM2 Agonism to Redirect Microglia from Synaptic Pruning to OPTN-Deficient Neuron Protection | TREM2 | 0.521 | $0.53 | SDA-2026-04-14-gap-p |
| #311 | Basal cGAS Derepression as Stratification Biomarker | cGAS promoter (CGAS), DNMT1, H3K9me3/Polycomb complex | 0.520 | $0.53 | SDA-2026-04-07-gap-p |
| #312 | Nucleocytoplasmic Transport Disruption | NUP107 | 0.520 | $0.53 | SDA-2026-04-08-gap-p |
| #313 | Piezoelectric Nanochannel BBB Disruption | CLDN5, OCLN | 0.519 | $0.53 | sda-2026-04-01-gap-0 |
| #314 | Vocal Cord Neuroplasticity Stimulation | CHR2/BDNF | 0.515 | $0.54 | sda-2026-04-01-gap-0 |
| #315 | EV-Mediated Epigenetic Reprogramming | EVs/miRNAs | 0.513 | $0.60 | sda-2026-04-12-ev-ad |
| #316 | Microbial Metabolite-Mediated α-Synuclein Disaggregation | SNCA, HSPA1A, DNMT1 | 0.511 | $0.52 | SDA-2026-04-01-gap-2 |
| #317 | Synthetic Biology Approach: Designer Mitochondrial Export Systems | Synthetic fusion proteins | 0.505 | $0.51 | SDA-2026-04-01-gap-2 |
| #318 | Autophagy-Lysosomal Flux Impairment Preventing Pathological TDP-43 Clearance | TFEB, LAMP1, LAMP2, GABARAPL1, CTSD | 0.500 | $0.52 | SDA-2026-04-07-gap-p |
| #319 | VDAC1 Hyper-Oligomerization via Direct TDP-43 Binding | VDAC1, VDAC2 | 0.496 | $0.52 | SDA-2026-04-08-gap-p |
| #320 | Mitochondrial Proteostasis Hijacking | TOMM40 | 0.490 | $0.51 | SDA-2026-04-08-gap-p |
| #321 | G3BP1-TDP-43 Cross-Seeding Drives Co-Aggregation That Prion-Spreads Across Neural Circuits | TARDBP | 0.490 | $0.51 | SDA-2026-04-06-gap-p |
| #322 | OPA1-Mediated Cristae Architecture Vulnerability | OPA1, MFN1/2, DRP1 (DNM1L), mitochondrial protease cleavage sites | 0.490 | $0.51 | SDA-2026-04-07-gap-p |
| #323 | Hyperphosphorylated TDP-43 Traps TRIM21 Into Inactive Complexes | TARDBP, TRIM21 | 0.487 | $0.51 | SDA-2026-04-06-gap-p |
| #324 | Kinesin-Dependent Peripheral Microtubule Transport Maintains Receptor Exclusion from SG Core | KIF5B/KIF5C | 0.486 | $0.51 | SDA-2026-04-08-gap-p |
| #325 | PINK1/PARK2-LC3 Mitophagy Enhancement | PINK1 | 0.485 | $0.50 | SDA-2026-04-03-gap-i |
| #326 | Microglia-Derived Extracellular Vesicle Engineering for Targeted Mitochondrial Delivery | RAB27A/LAMP2B | 0.482 | $0.47 | SDA-2026-04-01-gap-2 |
| #327 | Isoform-Selective Hsp70 Targeting Overcomes Stoichiometric Imbalance in Advanced Pathology | HSPA1A, DNAJB6, DNAJB8 | 0.481 | $0.53 | SDA-2026-04-06-gap-d |
| #328 | Enteric Nervous System Prion-Like Propagation Blockade | TLR4, SNCA | 0.480 | $0.48 | SDA-2026-04-01-gap-2 |
| #329 | FUS-ALS-Specific Ferroptosis Vulnerability Through NCOA4-Mediated Ferritinophagy Targeting | NCOA4 | 0.480 | $0.52 | SDA-2026-04-16-gap-f |
| #330 | Optogenetic Control of Mitochondrial Transfer Networks | ChR2 | 0.476 | $0.47 | SDA-2026-04-01-gap-2 |
| #331 | Ferroptosis as Context-Dependent and Motor Neuron-Subtype Selective | - | 0.475 | $0.52 | SDA-2026-04-18-gap-d |
| #332 | Mitochondrial Dysfunction Increasing Neuronal Vulnerability to TDP-43 Toxicity | MCU, CK1D, CSNK2A1, GSK3B, PARP1 | 0.470 | $0.50 | SDA-2026-04-07-gap-p |
| #333 | Prohibitin-2 Mitochondrial Cross-Seeding Hub Disruption | PHB2 | 0.469 | $0.46 | SDA-2026-04-01-gap-9 |
| #334 | RNA-Binding Competition Therapy for TDP-43 Cross-Seeding | TARDBP | 0.465 | $0.45 | SDA-2026-04-01-gap-9 |
| #335 | Necroptosis-cGAS Feedforward Loop Converts TDP-43 Pathology into Neuroinflammation | MLKL / RIPK1 | 0.460 | $0.50 | SDA-2026-04-07-gap-p |
| #336 | Mitochondrial Dysfunction in Neurodegeneration | NDUFV1 | 0.460 | $0.00 | - |
| #337 | DNMT3A-Mediated de novo Methylation Corrects 'Epigenetic Scars' at Polycomb Targets | DNMT3A | 0.460 | $0.53 | SDA-2026-04-10-gap-2 |
| #338 | TSPO-Mediated TDP-43 Mitochondrial Import | TSPO (TSPO), TDP-43-TSPO protein-protein interaction | 0.460 | $0.50 | SDA-2026-04-07-gap-p |
| #339 | C1q Inhibition Prevents Synaptic Mitochondrial Dysfunction via Microglial-Neuronal Cross-Talk Normalization | C1QA/C1QB/C1QC | 0.455 | $0.49 | SDA-2026-04-15-gap-p |
| #340 | Age-dependent downregulation of KPNA2 creates limbic neuron-specific nuclear import deficiency for TDP-43, explaining the predilection for hippocampal/amygdala pathology in AD versus motor neuron predominance in ALS | KPNA2 (karyopherin α2) | 0.452 | $0.50 | SDA-2026-04-07-gap-p |
| #341 | Paraneoplastic myelopathies involve CD8+ T cell recognition of viral/cancer antigens causing necroptotic neuronal death | HLA-A, HLA-B, CD8A, CD8B, PRF1, GZMB, RIPK3, MLKL | 0.450 | $0.49 | SDA-2026-04-08-gap-p |
| #342 | Astrocytic APOE4 Disruption of GABAergic Support Increasing Neuronal Vulnerability | SLC1A2 (GLT-1), GABRA1, GABRB3, GAD1 | 0.450 | $0.49 | SDA-2026-04-07-gap-p |
| #343 | Metabolic Reprogramming Toward GAPDH Inhibition | GAPDH, HK2 | 0.450 | $0.52 | SDA-2026-04-07-gap-p |
| #344 | Blood-Brain Barrier Disruption Enabling Peripheral Inflammatory Insult | PDGFRB, CLDN5, OCLN, FGB | 0.430 | $0.49 | SDA-2026-04-07-gap-p |
| #345 | DNA Damage Repair Dysfunction Creating TDP-43 Pathology Feed-Forward Loop | PARP1, ATM, XRCC1, LIG3 | 0.430 | $0.49 | SDA-2026-04-07-gap-p |
| #346 | FUS Mutations Impede G3BP1's Chaperone Function, Exposing Neurotoxic Stress Granule Intermediates | FUS | 0.430 | $0.48 | SDA-2026-04-06-gap-p |
| #347 | Microbiome-Derived Tryptophan Metabolite Neuroprotection | AHR, IL10, TGFB1 | 0.427 | $0.45 | SDA-2026-04-01-gap-2 |
| #348 | HDAC2-Specific Repression of PU.1 Pioneer Factor Target Sites Suppresses the IL-33/ST2-Phagocytic Axis; HDAC2 Deletion Specifically Unmasks These Enhancers | HDAC2 | 0.415 | $0.51 | SDA-2026-04-13-gap-p |
| #349 | IGFBPL1 Peptide Mimetics for Drug-Like BBB Permeability | IGFBPL1 | 0.397 | $0.51 | SDA-2026-04-06-gap-d |
| #350 | Bacterial Enzyme-Mediated Dopamine Precursor Synthesis | TH, AADC | 0.384 | $0.44 | SDA-2026-04-01-gap-2 |
| #351 | LRP1-Autophagy BBB Permeabilization for Antibody Transport | LRP1; ATG7; OPTN (autophagy pathway); CLDN5 (tight junctions) | 0.380 | $0.47 | SDA-2026-04-02-gap-b |
| #352 | Ferroptosis as Epiphenomenon of Terminal Collapse | - | 0.363 | $0.47 | SDA-2026-04-18-gap-d |
| #353 | Gap Junction Hemichannel Modulation for Controlled Mitochondrial Exchange | PANX1 | 0.361 | $0.44 | SDA-2026-04-01-gap-2 |
| #354 | Direct APOE4-TDP-43 Protein-Protein Interaction Promoting Aggregation Seeding | APOE, TARDBP | 0.360 | $0.49 | SDA-2026-04-07-gap-p |
| #355 | Ferroptosis as Primary Driver of Motor Neuron Death | - | 0.339 | $0.46 | SDA-2026-04-18-gap-d |
| #356 | P2RX7-PANX1 Channel Blockade for Neuroinflammatory Cascade Interruption | - | 0.105 | $0.42 | SDA-NEUROINFLAM-BIOM |